Kemoterápia okozta szenzoros neuropátiák jellegzetességei, diagnosztikája és kezelése

Ildikó Istenes, Zsolt Nagy, J. Demeter

Research output: Review article

1 Citation (Scopus)

Abstract

Longer remissions and better overall survival rates can be achieved with the introduction of new, effective treatments and targeted therapies in the past 1-2 decades, however, the incidence of side effects is also increasing parallelly. Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially debilitating side effect due to peripheral somatic or autonomic nerve dysfunction. CIPN becomes increasingly important, as it affects patients' quality of life, and it is very often a dose limiting factor with the potential for reduced treatment efficacy. The pathomechanism, diagnosis, prevention and treatment possibilities are described in this review with special attention to the different groups of drugs.

Original languageHungarian
Pages (from-to)165-175
Number of pages11
JournalMagyar Onkologia
Volume60
Issue number2
Publication statusPublished - jún. 6 2016

Fingerprint

Peripheral Nervous System Diseases
Drug Therapy
Autonomic Pathways
Peripheral Nerves
Therapeutics
Survival Rate
Quality of Life
Incidence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Kemoterápia okozta szenzoros neuropátiák jellegzetességei, diagnosztikája és kezelése. / Istenes, Ildikó; Nagy, Zsolt; Demeter, J.

In: Magyar Onkologia, Vol. 60, No. 2, 06.06.2016, p. 165-175.

Research output: Review article

@article{b97ff92dee9d418e9837751bd54d5b2b,
title = "Kemoter{\'a}pia okozta szenzoros neurop{\'a}ti{\'a}k jellegzetess{\'e}gei, diagnosztik{\'a}ja {\'e}s kezel{\'e}se",
abstract = "Longer remissions and better overall survival rates can be achieved with the introduction of new, effective treatments and targeted therapies in the past 1-2 decades, however, the incidence of side effects is also increasing parallelly. Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially debilitating side effect due to peripheral somatic or autonomic nerve dysfunction. CIPN becomes increasingly important, as it affects patients' quality of life, and it is very often a dose limiting factor with the potential for reduced treatment efficacy. The pathomechanism, diagnosis, prevention and treatment possibilities are described in this review with special attention to the different groups of drugs.",
author = "Ildik{\'o} Istenes and Zsolt Nagy and J. Demeter",
year = "2016",
month = "6",
day = "6",
language = "Hungarian",
volume = "60",
pages = "165--175",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - Kemoterápia okozta szenzoros neuropátiák jellegzetességei, diagnosztikája és kezelése

AU - Istenes, Ildikó

AU - Nagy, Zsolt

AU - Demeter, J.

PY - 2016/6/6

Y1 - 2016/6/6

N2 - Longer remissions and better overall survival rates can be achieved with the introduction of new, effective treatments and targeted therapies in the past 1-2 decades, however, the incidence of side effects is also increasing parallelly. Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially debilitating side effect due to peripheral somatic or autonomic nerve dysfunction. CIPN becomes increasingly important, as it affects patients' quality of life, and it is very often a dose limiting factor with the potential for reduced treatment efficacy. The pathomechanism, diagnosis, prevention and treatment possibilities are described in this review with special attention to the different groups of drugs.

AB - Longer remissions and better overall survival rates can be achieved with the introduction of new, effective treatments and targeted therapies in the past 1-2 decades, however, the incidence of side effects is also increasing parallelly. Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially debilitating side effect due to peripheral somatic or autonomic nerve dysfunction. CIPN becomes increasingly important, as it affects patients' quality of life, and it is very often a dose limiting factor with the potential for reduced treatment efficacy. The pathomechanism, diagnosis, prevention and treatment possibilities are described in this review with special attention to the different groups of drugs.

UR - http://www.scopus.com/inward/record.url?scp=85046818915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046818915&partnerID=8YFLogxK

M3 - Review article

C2 - 27275643

AN - SCOPUS:85046818915

VL - 60

SP - 165

EP - 175

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 2

ER -